Zebrafish (Danio rerio) larvae have emerged as a powerful vertebrate model in early-stage drug discovery. Approximately 84% of human disease-related proteins have zebrafish orthologs, and the larvae develop a functional blood–brain barrier (BBB) as early as 3 days post-fertilization. They also express a full complement of cytochrome P450 enzymes involved in drug metabolism, making them highly suitable for pharmacological screening (1, 2). Their rapid development, small size, and optical transparency enable efficient, high-throughput in vivo experimentation.
One of the greatest strengths of zebrafish larvae is their scalability. Hundreds of larvae can be maintained in multi-well plates and dosed non-invasively via bath immersion. This allows for cost-effective screening of large compound libraries. Phenotypic profiling based on behavioral and physiological readouts has led to the discovery of neuroactive and cardiovascular agents through distinct activity signatures or “phenotypic barcodes” (3).
Behavioral assays provide a robust measure of drug efficacy. Zebrafish larvae exhibit various quantifiable behaviors including spontaneous locomotion, photomotor responses, startle reflexes, and circadian rhythms. These behaviors are captured through automated imaging platforms like DanioVision, which, coupled with EthoVision XT tracking software, enables precise and reproducible analysis of up to 96 larvae simultaneously under standardized light and acoustic stimuli (4). High-content imaging combined with transcriptomics supports mechanistic insights into drug action, such as effects on neurotransmitter systems or stress-response pathways.
Zebrafish also offer regulatory and ethical advantages. In many jurisdictions, larvae under five days post-fertilization are not classified as protected animals, enabling early-stage screening in live vertebrates without the regulatory burden associated with mammalian studies (3).
Despite some limitations (5), zebrafish larvae serve a critical role in refining the drug discovery process. They enable early, cost-effective screening while reducing reliance on rodent models. Their application is especially valuable for identifying neuroactive, cardiotoxic, or developmental agents in an intact vertebrate system (6).
References
- Quiñonez-Silvero C, Hübner K, Herzog W. Development of the brain vasculature and the blood-brain barrier in zebrafish. Dev Biol. 2020 Jan 15;457(2):181-190. doi: 10.1016/j.ydbio.2019.03.005. Epub 2019 Mar 9. PMID: 30862465.
- Goldstone JV, McArthur AG, Kubota A, Zanette J, Parente T, Jönsson ME, Nelson DR, Stegeman JJ. Identification and developmental expression of the full complement of Cytochrome P450 genes in Zebrafish. BMC Genomics. 2010 Nov 18;11:643. doi: 10.1186/1471-2164-11-643. PMID: 21087487; PMCID: PMC3012610.
- Kokel D, Bryan J, Laggner C, White R, Cheung CY, Mateus R, Healey D, Kim S, Werdich AA, Haggarty SJ, Macrae CA, Shoichet B, Peterson RT. Rapid behavior-based identification of neuroactive small molecules in the zebrafish. Nat Chem Biol. 2010 Mar;6(3):231-237. doi: 10.1038/nchembio.307. Epub 2010 Jan 17. PMID: 20081854; PMCID: PMC2834185.
- Basnet RM, Zizioli D, Taweedet S, Finazzi D, Memo M. Zebrafish Larvae as a Behavioral Model in Neuropharmacology. Biomedicines. 2019 Mar 26;7(1):23. doi: 10.3390/biomedicines7010023. PMID: 30917585; PMCID: PMC6465999.
- Pelka KE, Henn K, Keck A, Sapel B, Braunbeck T. Size does matter – Determination of the critical molecular size for the uptake of chemicals across the chorion of zebrafish (Danio rerio) embryos. Aquat Toxicol. 2017 Apr;185:1-10. doi: 10.1016/j.aquatox.2016.12.015. Epub 2016 Dec 21. PMID: 28142078.
- Miyawaki I. Application of zebrafish to safety evaluation in drug discovery. J Toxicol Pathol. 2020 Oct;33(4):197-210. doi: 10.1293/tox.2020-0021. Epub 2020 Jul 25. PMID: 33239838; PMCID: PMC7677624.